On January 29th 2016 Terumo Corporation and Quirem Medical expanded their Strategic Alliance. Terumo thereby became the exclusive global distributor for the radioembolization solutions developed by Quirem Medical.

Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in interventional procedures, cardiovascular surgery, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange and are a component of the Nikkei, Japan’s leading stock index.

By building on its long term partnership with the University Medical Center Utrecht and supported by a strong patent base, both parties are committed to collaborate in the further development of the Holmium technology base to bring better cancer treatment solutions to patients worldwide.

University Medical Center Utrecht strives to achieve the highest levels in, patient care, scientific research and education. By dedicating ourselves to continuous improvements, we can pioneer cutting-edge treatments, foster groundbreaking findings, and deliver a standard of care that meets the healthcare needs for today, and the future.

On October 22nd 2019, Radboud University Medical Center (Nijmegen, The Netherlands) and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on holmium-166 microspheres. The research into holmium microspheres in Nijmegen takes place in the Radiology andNuclear Medicine department. Radboud University Medical Center offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications.

The hybrid operating theatres in Nijmegen, called MITeC, enable clinicians and researcher to use MRI imaging to show the location of the radioactive holmium microspheres during a SIRT treatment. This may facilitate SIRT treatments that are better tailored to the individual.